Please enable JS

Investors & Media

SEC Filings

Form DEF 14A
CRISPR THERAPEUTICS AG filed this Form DEF 14A on 04/18/2017
Document Outline
Entire Document (816.1 KB)
Subdocument 1 - DEF 14A - DEF 14A
Page 1 - UNITED STATES
Page 2 - CRISPR THERAPEUTICS AG
Page 3 - 6.a Binding vote on total non-performance-related compensation for members of the Board of Directors
Page 4 - 6.e Binding vote on equity for members of the Executive Committee from the 2017 Annual General Meeti
Page 5 - N/A
Page 6 - Important Notice Regarding Internet Availability of Proxy Materials
Page 7 - TABLE OF CONTENTS
Page 8 - CRISPR THERAPEUTICS AG
Page 9 - N/A
Page 10 - IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING
Page 11 - If your shares are held in street name,
Page 12 - Regardless of whether your shares are held in street name, you are welcome to attend the 2017 Annual
Page 13 - If your shares are held in street name,
Page 14 - BOARD OF DIRECTORS AND CORPORATE GOVERNANCE
Page 15 - N. Anthony Coles, M.D., Chairman and Director:
Page 16 - Kurt von Emster, CFA, Director:
Page 17 - Corporate Governance Matters
Page 18 - Board Determination of Independence
Page 19 - Committees of the Board of Directors
Page 20 - Compensation Committee
Page 21 - Nominating and Corporate Governance Committee
Page 22 - Director Nomination Process
Page 23 - Compensation Committee Interlocks and Insider Participation
Page 24 - Registration Rights Agreement
Page 25 - Demand Registration Rights
Page 26 - Bayer Subscription Agreement
Page 27 - Initial Public Offering
Page 28 - EXECUTIVE COMPENSATION
Page 29 - Samarth Kulkarni, Ph.D., Chief Business Officer:
Page 30 - Summary Compensation Table
Page 31 - Annual Bonuses.
Page 32 - Outstanding Equity Awards at Year-End
Page 33 - Marc Becker.
Page 34 - Dr. Kala Subramanian.
Page 35 - Retirement Plans
Page 36 - Compensation Risk Assessment
Page 37 - DIRECTOR COMPENSATION
Page 38 - N/A
Page 39 - SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS
Page 40 - REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS
Page 41 - MATTERS TO BE VOTED ON
Page 42 - Proposal 2: Approval of the Appropriation of Financial Results
Page 43 - Proposal 3: Discharge of the Members of the Board of Directors and Executive Committee
Page 44 - Proposal 4: Re-Election of Eight Directors
Page 45 - 4.e Re-election of Kurt von Emster
Page 46 - Proposal 5: Re-Election of Members of the Compensation Committee
Page 47 - Voting Requirement to Approve Proposals
Page 48 - Proposal 6: Approval of the Compensation for the Board of Directors and the Members of the Executive
Page 49 - 6.d Binding vote on total variable compensation for members of the Executive Committee for the curre
Page 50 - Proposal 7: Approval of an Increase of the Conditional Share Capital for Employee Benefit Plans
Page 51 - italic
Page 52 - Proposal 8: Approval of the CRISPR Therapeutics AG Amended and Restated 2016 Stock Option and Incent
Page 53 - Qualified Performance-Based Compensation under Code Section 162(m)
Page 54 - Summary of the Amended and Restated Plan
Page 55 - Stock Appreciation Rights.
Page 56 - Change of Control Provisions.
Page 57 - Tax Aspects Under the Code
Page 58 - Other Awards.
Page 59 - Proposal 9: Re-Election of Independent Voting Rights Representative
Page 60 - Proposal 10: The re-election of Ernst Young AG as our statutory auditor for the term of office of on
Page 61 - Voting Requirement to Approve Proposal
Page 62 - Proposal 11: Approval of the change in the registered office
Page 63 - italic
Page 64 - STOCK OWNERSHIP AND REPORTING
Page 65 - N/A
Page 66 - Section 16(a) Beneficial Ownership Reporting Compliance
Page 67 - Restrictions on Voting Rights
Page 68 - N/A
Page 69 - OTHER MATTERS
Page 70 - Appendix A
Page 71 - Fair Market Value
Page 72 - Performance Cycle
Page 73 - Unrestricted Stock Award
Page 74 - Award Certificate
Page 75 - Maximum Awards to Non-Employee Directors
Page 76 - ELIGIBILITY
Page 77 - By the optionee delivering to the Company a properly executed exercise notice together with irrevoca
Page 78 - RESTRICTED STOCK AWARDS
Page 79 - Election to Receive Restricted Stock Units in Lieu of Compensation
Page 80 - PERFORMANCE-BASED AWARDS TO COVERED EMPLOYEES
Page 81 - Termination
Page 82 - SECTION 409A AWARDS
Page 83 - STATUS OF PLAN
Page 84 - CRISPR Therapeutics AG
Page 85 - ANNUAL MEETING PROXY CARD
Page 86 - 6.bBinding vote on equity for members of the Board of Directors from the 2017 Annual General Meeting
Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet